Alteration of DNA Methyltransferases by Eribulin Elicits Broad DNA Methylation Changes with Potential Therapeutic Implications for Triple-Negative Breast Cancer is a research paper published in Epigenomics (2024). On theSindex it has a DataRank of 0.381. It has been cited 6 times, with 6 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph β no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full β never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0.0887
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) β log1p(Cq) divided by its reference count β out of 6 citers.
National Institute of General Medical Sciences
Grant: P20GM130454
National Institutes of Health
Grant: S10OD025235
National Institutes of Health
Grant: R00CA201574
National Institutes of Health
Grant: R01CA267691
National Institutes of Health
Grant: R01CA216265
National Institutes of Health
Grant: R01CA253976
NCI NIH HHS
Grant: P30 CA023108
NIH HHS
Grant: R00CA201574, R01CA216265
Fields of Study
MeSH Terms
Keywords
Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer
Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer